ATX — Amplia Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$52.37m
- AU$41.52m
- AU$3.77m
- 34
- 32
- 66
- 40
Annual income statement for Amplia Therapeutics, fiscal year end - March 31st, AUD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.53 | 1.98 | 1.15 | 4.44 | 3.77 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.82 | 5.63 | 7.48 | 9.02 | 10.6 |
| Operating Profit | -2.28 | -3.64 | -6.33 | -4.59 | -6.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.28 | -3.64 | -6.24 | -4.5 | -6.57 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.28 | -3.64 | -6.24 | -4.5 | -6.57 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.28 | -3.64 | -6.24 | -4.5 | -6.57 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.28 | -3.64 | -6.24 | -4.5 | -6.57 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.023 | -0.024 | -0.031 | -0.022 | -0.021 |